Business Description
West Pharmaceutical Services Inc
NAICS : 339112
SIC : 3841
ISIN : US9553061055
Description
Financial Strength
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 2.76 | |||||
Equity-to-Asset | 0.75 | |||||
Debt-to-Equity | 0.11 | |||||
Debt-to-EBITDA | 0.37 | |||||
Interest Coverage | 78.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 20.03 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC |
Growth Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 11.4 | |||||
3-Year EBITDA Growth Rate | 17.9 | |||||
3-Year EPS without NRI Growth Rate | 19.3 | |||||
3-Year FCF Growth Rate | 11.9 | |||||
3-Year Book Growth Rate | 16.1 | |||||
Future 3-5Y EPS without NRI Growth Rate | 6.87 | |||||
Future 3-5Y Total Revenue Growth Rate | 6.39 |
Momentum Rank
7/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 24.98 | |||||
9-Day RSI | 30.61 | |||||
14-Day RSI | 35.98 | |||||
6-1 Month Momentum % | 18.61 | |||||
12-1 Month Momentum % | 8.68 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 2.88 | |||||
Quick Ratio | 2.24 | |||||
Cash Ratio | 1.27 | |||||
Days Inventory | 87.32 | |||||
Days Sales Outstanding | 64 | |||||
Days Payable | 45.29 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Dividend Yield % | 0.21 | |||||
Dividend Payout Ratio | 0.1 | |||||
3-Year Dividend Growth Rate | 5.8 | |||||
Forward Dividend Yield % | 0.22 | |||||
5-Year Yield-on-Cost % | 0.28 | |||||
3-Year Average Share Buyback Ratio | 0.2 | |||||
Shareholder Yield % | 1.93 |
Profitability Rank
9/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Gross Margin % | 38.28 | |||||
Operating Margin % | 23.98 | |||||
Net Margin % | 20.12 | |||||
FCF Margin % | 13.18 | |||||
ROE % | 21.26 | |||||
ROA % | 15.96 | |||||
ROIC % | 23.46 | |||||
ROC (Joel Greenblatt) % | 36.53 | |||||
ROCE % | 22.34 | |||||
Years of Profitability over Past 10-Year | 10 |
GF Value Rank
6/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
PE Ratio | 47.55 | |||||
Forward PE Ratio | 47.28 | |||||
PE Ratio without NRI | 47.05 | |||||
Shiller PE Ratio | 74.32 | |||||
Price-to-Owner-Earnings | 52.73 | |||||
PEG Ratio | 2.14 | |||||
PS Ratio | 9.22 | |||||
PB Ratio | 9.19 | |||||
Price-to-Tangible-Book | 9.61 | |||||
Price-to-Free-Cash-Flow | 65.34 | |||||
Price-to-Operating-Cash-Flow | 34.94 | |||||
EV-to-EBIT | 39.24 | |||||
EV-to-Forward-EBIT | 37.85 | |||||
EV-to-EBITDA | 32.46 | |||||
EV-to-Forward-EBITDA | 31.06 | |||||
EV-to-Revenue | 9.06 | |||||
EV-to-Forward-Revenue | 8.81 | |||||
EV-to-FCF | 63.99 | |||||
Price-to-Projected-FCF | 3.87 | |||||
Price-to-DCF (Earnings Based) | 1.43 | |||||
Price-to-DCF (FCF Based) | 2.09 | |||||
Price-to-Median-PS-Value | 1.81 | |||||
Price-to-Peter-Lynch-Fair-Value | 1.97 | |||||
Price-to-Graham-Number | 4.36 | |||||
Price-to-Net-Current-Asset-Value | 26.82 | |||||
Earnings Yield (Greenblatt) % | 2.55 | |||||
FCF Yield % | 1.47 | |||||
Forward Rate of Return (Yacktman) % | 21.21 |